TC Biopharm (Holdings) Plc
NASDAQ: TCBP0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Bryan Leland Kobel
- Employees
- 41
- Headquarters
- Motherwell, United Kingdom
- IPO year
- 2022
- Market cap
- $256.5K
- Website
- https://www.tcbiopharm.com
Loading TCBP…
Loading profile data…Frequently asked questions about TCBP
What does TC Biopharm (Holdings) Plc (TCBP) do?
Operating as a clinical-stage biopharmaceutical entity, TC Biopharm (Holdings) Plc is dedicated to pioneering immunotherapy solutions, leveraging its proprietary allogeneic gamma delta T cell platform. Its developmental portfolio includes OmnImmune, an unmodified cellular therapy aimed at acute myeloid leukemia, and ImmuniStim, another unmodifie...
Where does TCBP trade?
TC Biopharm (Holdings) Plc (TCBP) trades on the NASDAQ Capital Market.
What sector is TCBP in?
TC Biopharm (Holdings) Plc (TCBP) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of TC Biopharm (Holdings) Plc?
Bryan Leland Kobel is the chief executive officer of TC Biopharm (Holdings) Plc (TCBP).
Where is TC Biopharm (Holdings) Plc headquartered?
TC Biopharm (Holdings) Plc is headquartered in United Kingdom.
Does TCBP pay a dividend?
TC Biopharm (Holdings) Plc (TCBP) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did TCBP go public?
TC Biopharm (Holdings) Plc (TCBP) completed its initial public offering in 2022.
Is TCBP an ADR?
Yes — TCBP is an American Depositary Receipt; its underlying shares trade on a non-US exchange. TC Biopharm (Holdings) Plc reporting and dividends follow the underlying issuer.